• English
  • 简体中文
Login Register
Current Location: Home > Marketing Drugs(EU) Feedback Help Print
Product No EMEA/H/C/003956
Brand Name Accofil
Nonproprietary Name filgrastim
API filgrastim
ATC Code L03AA02
Indications Accofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of Accofil are similar in adults and children receiving cytotoxic chemotherapy. Accofil is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).In patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Accofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Accofil is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
Orphan Drug no
Generics no
Marketing Authorization Holder Accord Healthcare Ltd
Status Authorised
Authorization Date 2014-09-18
Version 4
Condition Approval no
Exceptions no
Biosimilar yes
Details 查看 (公众评估报告、授权细节、产品规格/剂型、标签、历史评估信息)